US 12,440,603 B2
Nerve grafts and methods of preparation thereof
Jennifer Faleris, Alachua, FL (US); and Kasra Tajdaran, Alachua, FL (US)
Assigned to Axogen Corporation, Alachua, FL (US)
Filed by Axogen Corporation, Alachua, FL (US)
Filed on Aug. 25, 2021, as Appl. No. 17/411,718.
Claims priority of provisional application 63/071,635, filed on Aug. 28, 2020.
Prior Publication US 2022/0062505 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 27/36 (2006.01); A61L 27/54 (2006.01)
CPC A61L 27/3675 (2013.01) [A61L 27/3604 (2013.01); A61L 27/3687 (2013.01); A61L 27/3695 (2013.01); A61L 27/54 (2013.01); A61L 2430/32 (2013.01); A61L 2430/40 (2013.01)] 46 Claims
 
1. A method for preparing a nerve graft, the method comprising:
treating nerve tissue with a digestion solution comprising (a) trypsin and alpha-chymotrypsin (ACT), or (b) trypsin, ACT and ethylenediaminetetraacetic acid (EDTA), to substantially remove one or more susceptible proteins from the nerve tissue, wherein the digestion solution comprises one or more of:
about 3.5×103 USP units/mL to about 4.5×103 USP units/mL of trypsin;
about 50 USP units/mL to about 55 USP units/mL of ACT; and
about 1.2 mM to about 1.5 mM of EDTA,
wherein the treated nerve tissue is substantially free of one or more of laminin alpha-1, laminin alpha-2, laminin alpha-4, laminin alpha-5, laminin beta-1, laminin beta-2, laminin gamma-1, collagen type IV alpha-1 chain, collagen type IV alpha-1/5 chain, collagen type IV alpha-2 chain, collagen type IV alpha-3 chain, fibronectin 1, perlecan, nidogen-1, or nidogen-2.